Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Prognostic relevance of a BPDCN-like immunophenotype in cytogenetically normal AML

Fabio Guolo • 11 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia

Fabio Guolo, MD, of the University of Genoa, Genoa, Italy, outlines the prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like (BPDCN) immunophenotype in cytogenetically normal acute myeloid leukemia (AML) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Fabio Guolo

Selecting patients with secondary AML for CPX-351 1:14
Selecting patients with secondary AML for CPX-351
Fabio Guolo • 13 Jun 2025
The efficacy of CPX-351 in secondary AML defined according to the WHO 2022 classification 1:15
The efficacy of CPX-351 in secondary AML defined according to the WHO 2022 classification
Fabio Guolo • 13 Jun 2025
Comparing real-world outcomes with CPX-351 versus fludarabine-based induction in secondary AML 1:19
Comparing real-world outcomes with CPX-351 versus fludarabine-based induction in secondary AML
Fabio Guolo • 6 Dec 2024
Real-world evidence of the efficacy of CPX-351 in secondary AML 1:01
Real-world evidence of the efficacy of CPX-351 in secondary AML
Fabio Guolo • 6 Dec 2024

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals